.jpg)
.png)
Top Stories
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved evolocumab for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial... more
MIAMI, Fla. – (May 16, 2019) – The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value. While initial pricing of... more
A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach. Ideas, Inventions And Innovations Blog - October 15, 2012
Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session. Inclisiran, the first... more
The NLA and Foundation of the NLA Recognize Renowned Physician and Researcher Dr. Joseph L. Witztum With Highest Honor, W. Virgil Brown Distinguished Achievement Award Speakers from around the world will be presenting their latest research and science at the upcoming National Lipid Association (... more
An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.... more
Please help us gain insight into the use of plaque information obtained from coronary CTA in managing your patients by participating in “Potential Clinical Applications of Plaque Imaging by CTA: A Survey,” conducted by Harvey Hecht and Jagat Narula from Mount Sinai Medical Center... more
Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH... more
Familial Hypercholesterolemia (FH) is among the most common genetic lipid disorders; left untreated, FH patients have a 20-fold increased risk for CHD. Primary Issues Website - July 24, 2011
Esperion has announced that NEXLIZET™ (bempedoic acid and ezetimibe) Is now available in pharmacies in the United States. NEXLIZET™ is an oral, once-daily, fixed-dose combination tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous... more